U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07213349) titled 'Daridorexant for Alzheimer Disease Prevention' on Sept. 24.
Brief Summary: This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.
Study Start Date: Oct. 07
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease (AD)
Intervention:
DRUG: Daridorexant 50 mg
Study drug (Daridorexant 50 mg) taken orally each night 30 minutes befor...